Prolonged KRAS-MAPK Inhibition Induces Interferon Signaling That Promotes Cell State Transition and Confers Therapeutic Vulnerabilities
Authors:
- Ashenafi BulleABAshenafi Bulle
- Yali ChenYCYali Chen
- Huaping LiHLHuaping Li
- Timothy Hung-Po ChenTCTimothy Hung-Po Chen
- Iftikhar Ali KhawarIKIftikhar Ali Khawar
- Lin LiLLLin Li
- Yu WangYWYu Wang
- Peng LiuPLPeng Liu
- Vikas Kumar SomaniVSVikas Kumar Somani
- Richard KurupiRKRichard Kurupi
- Yutong GengYGYutong Geng
- Ofejiro Blessing PereyeOPOfejiro Blessing Pereye
Open Access
- 13 May 2026
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- p. OF1-OF17
Abstract
Acquired resistance limits the therapeutic efficacy of KRAS-MAPK inhibitors in pancreatic ductal adenocarcinoma (PDAC). As transcriptional plasticity and epithelial-to-mesenchymal transition (EMT) have been implicated in resistance, we sought to study the molecular mechanisms driving these changes to uncover actionable vulnerabilities. Sustained KRAS-MAPK inhibition induced interferon (IFN) and NF-κB signaling and promoted cell state change mimicking an EMT state associated with drug resistance. Network analysis identified the IFN-inducible E3 ubiquitin ligase TRIM22 as a central regulator of this response. Mechanistically, TRIM22 promoted proteasomal degradation of IκBα, resulting in sustained NF-κB and EMT program activation that coincided with a basal-like transcriptional cell state. TRIM22 expression was driven by IRF1 and IRF9 following relief of ERK-mediated transcriptional repression during pathway inhibition. EMT induction was accompanied by marked upregulation of TROP2 (TACSTD2), an NF-κB target gene enriched in basal-like PDAC cell states. Combining TROP2-directed antibody–drug conjugate sacituzumab govitecan with KRAS or ERK inhibitors significantly suppressed PDAC tumor growth in xenograft models. Overall, prolonged KRAS-MAPK inhibition activates an IFN–TRIM22–NF-κB axis that drives EMT and therapeutic resistance in PDAC, while revealing TROP2 as a clinically actionable vulnerability to overcome acquired resistance. Significance: TRIM22 drives interferon-induced EMT and NF-κB–dependent TROP2 upregulation to drive resistance to KRAS-MAPK inhibition in pancreatic cancer, which can be overcome by combining sacituzumab govitecan with KRAS-MAPK inhibitors.Keywords
Funding Information
- National Cancer Institute (R01CA262414)
- Foundation for Barnes-Jewish Hospital (NA)
- National Cancer Institute (U54CA224083)
- National Cancer Institute (R37CA219697)
This publication has 34 references indexed in Scilit:
- STRING v10: protein–protein interaction networks, integrated over the tree of lifeNucleic Acids Research, 2014
- Phosphorylation releases constraints to domain motion in ERK2Proceedings of the National Academy of Sciences, 2014
- Influence of type‐I Interferon receptor expression level on the response to type‐I Interferons in human pancreatic cancer cellsJournal of Cellular and Molecular Medicine, 2014
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growthNature, 2010
- Profiling the Human Protein-DNA Interactome Reveals ERK2 as a Transcriptional Repressor of Interferon SignalingCell, 2009
- Biomarkers for epithelial-mesenchymal transitionsJournal of Clinical Investigation, 2009
- Identification of TRIM22 as a RING finger E3 ubiquitin ligaseBiochemical and Biophysical Research Communications, 2008
- Mechanisms of type-I- and type-II-interferon-mediated signallingNature Reviews Immunology, 2005
- Growth Factor–induced p42/p44 MAPK Nuclear Translocation and Retention Requires Both MAPK Activation and Neosynthesis of Nuclear Anchoring ProteinsJournal of Cell Biology, 1998
- Transcription factors induced by interferons α and γNucleic Acids Research, 1990